Pregnancy loss in dairy cattle in the Waikato region of New Zealand

AIM

To define the incidence rate of pregnancy loss and risk factors for those losses in pasture-fed dairy cattle in the Waikato region of New Zealand.

METHODS

Cows (n=2,004) from 10 pasture-fed, spring-calving dairy herds in the Waikato were enrolled following confirmation of pregnancy 29-45 days after insemination, for inseminations that occurred within the first 16 days of the seasonal breeding period. Transrectal ultrasonographic examinations for pregnancy were conducted at approximately 6, 8, 10, 14 and 22 weeks gestation, and subsequent calving data were recovered. Pregnancy loss was defined as having occurred when a confirmed pregnancy was not re-diagnosed, when gross abortion was detected, or when a cow calved <265 days after the confirmed conception date. Data were analysed using reverse stepwise logistic regression and Cox's proportional hazards analysis.

RESULTS

A total of 128 (6.4%) pregnancy losses were detected. The incidence rate was higher in early compared to late gestation (10.9 vs 2.8 losses/10,000 cow-days between Weeks 6-10 vs Weeks 10-14, respectively; p<0.001). Higher rates of loss were associated with the occurrence of clinical mastitis (Hazards ratio (HR)=1.57; p=0.071), being treated for anoestrus (HR=1.69; p=0.007), and in cows that had calving-to-conception intervals < or =63 days compared with those that had calving-to-conception intervals >92 days (HR=2.49; p=0.06). In addition, the rate of pregnancy loss differed between herds (p=0.05).

CONCLUSIONS

The highest rate of pregnancy loss occurred in early gestation. Clinical mastitis, anoestrus and calving late in the calving season were risk factors for pregnancy loss.

CLINICAL RELEVANCE

Pregnancy diagnosis using ultrasonography can be undertaken from 28 days post-insemination. However, due to the high rate of pregnancy loss at this stage of gestation, herdowners need to be warned of possible losses, and cows should be re-examined to confirm pregnancy before certification of pregnancy status is given.

Gross abnormalities, bacteriology and histological lesions of uteri of dairy cows failing to conceive or maintain pregnancy

AIM

To describe the gross pathology, bacteriology and histopathology of the reproductive tracts of dairy cows that failed to conceive or maintain pregnancy.

METHODS

The reproductive tracts of 105 cows that were not pregnant at the end of the seasonal breeding programme were retrieved following slaughter. The tracts were examined grossly, both horns of the uterine lumen were swabbed for bacteriology, and tissue was collected from each horn and the body of the uterus for histopathology. Grossly enlarged uteri and tracts containing purulent vaginal content were excluded. Histopathology was performed on three sections of uterine tissue from each of three cows in which no gross pathological changes were detected and from which no bacteria were isolated, from three cows in which no gross pathology was detected but from which bacteria were isolated, and from three cows in which gross pathological changes were detected but from which no bacteria were isolated.

RESULTS

Thirty-six (34%) cows had one or more gross lesions which involved the ovary, uterine tube, uterus or vagina. Bacteria were isolated from the uteri of 22 (21%) cows. Isolates included Arcanobacterium pyogenes (n = 1), Escherichia coli (n = 1), Fusobacterium spp (n = 1), Haemophilus somnus (n = 5), Streptococcus acidominimus (n = 12), S. bovis (n = 2), S. uberis (n = 1) and S. salivarious (n = 1). In only five cows were both gross pathology and bacteria detected. There was no relationship between the isolation of bacteria and the diagnosis of gross pathology of the uterus. There were no differences in the degree of histopathological changes in the uteri from the three groups of cows examined, and lesions present were minor.

CONCLUSIONS

Gross pathological changes and intra-uterine bacteria were found in 34% and 20% of cows, respectively, but the correlation between the two was poor. Histopathological changes were unremarkable, suggesting the bacteriological findings were coincidental, that causative agents of infertility were not present at the time of examination, or that unrelated causes such as nutritional anoestrus may have been responsible for the failure of some cows to conceive.

Reproductive Performance of Anestrous Dairy Cows Treated with Progesterone and Estradiol Benzoate

Anestrus is a major reproduction problem in pasture-based dairy operations that results in poorer reproductive outcomes than herdmates detected in estrus before the start of the seasonal breeding program. The objective of the current study was to assess a combined progesterone and estradiol benzoate treatment program including resynchrony with no treatment. Anestrous pasture-fed dairy cattle (n = 756) in 9 herds were blocked by herd and age and assigned within sequentially presented pairs of cows to be treated with an intravaginal progesterone-releasing insert for 8 d plus 2 mg of estradiol benzoate injected i.m. at insert insertion and 1 mg of estradiol benzoate injected 1 d after insert removal (d -1). Those cows detected in estrus from 0 to 3 d had a used progester-one-releasing insert reinserted for 6 d commencing on d 16 with 0.5 mg of estradiol benzoate injected i.m. 1 d after insert removal (treatment). The other cow within the pair was left as an untreated control (control). Treatment increased the risk of insemination and pregnancy by 28 d into the breeding program and resulted in conception 15 d earlier compared with controls. In contrast, treatment did not increase the risk of pregnancy after 56 d into the breeding program or at the end of the breeding season. It is concluded that treatment of anestrous dairy cattle with progesterone and estradiol benzoate combined with reinsertion of the progesterone insert resulted in earlier conception, but no difference in the final pregnancy rate compared with no treatment.

Reproductive performance in anestrous dairy cows following treatment with two protocols and two doses of progesterone

The objectives of this study were to evaluate the effect using two doses of progesterone (P4) releasing devices in two different programs on reproductive performance of anestrous dairy cows. Cows (n = 1555) not detected in estrus by 10 d before the planned start of the seasonal breeding program and in which no CL was palpable were treated with an intravaginal P4-releasing device ('Single'; approximately 1.56 g of P4) or a modified device with triple the normal P4 dose ('Triple'; approximately 4.7 g of P4). The devices were in place for either 6 d ('Short') or 8 d ('Long'), with 1mg estradiol benzoate (EB) given 24 h after device removal. The 'Long' program also included treatment with 2 mg EB at device insertion. The Long program resulted in a higher first service conception rate (RR = 1.18 (95% CI = 1.03-1.33); P = 0.02), but had no effect on the 28-d, 56-d or final pregnancy rate compared to the Short program. There were no effects of dose of P4 on any outcome. In conclusion, the Long compared to the Short program, but not the dose of P4, improved first service conception rates in anestrous cows.

Effect of exogenous progesterone and oestradiol on plasma progesterone concentrations and follicle wave dynamics in anovulatory anoestrous post-partum dairy cattle

The effect of exogenous progesterone (P4) and of oestradiol benzoate (ODB) on plasma progesterone concentration and follicle dynamics was studied in anovulatory anoestrus (AA) post-partum pasture-fed dairy cattle. Cows (n=32) were defined AA based on not detecting a corpus luteum upon transrectal ultrasonography of the ovaries. Cows were randomly assigned to treatment with an intravaginal P4-releasing device containing 1.56 g of P4 (1Q; Cuemate, Pfizer Animal Health, Auckland, NZ; n=11) or with modified devices with double (2Q; n=11) or triple (3Q; n=10) the normal P4 dose for 8 days. Half of each group received 2 mg ODB at device insertion (Day 0) while the other half did not receive ODB at this time. All cows were treated with 1 mg ODB 1 day after intravaginal device removal (Day 9). Ultrasonography occurred daily until either ovulation or Day 15 whichever occurred sooner. Blood samples were drawn on Days 0, 1, 3, 5, 7, 8, 9, 15 and 22 for plasma P4 determination. Increasing P4 dose was associated with an increase in plasma P4 concentration during the time of device insertion (P <0.05). The highest P4 dose was associated with a delay in emergence of, but a shorter interval from emergence to maximum diameter and ovulation of, the subsequent dominant follicle (DF2) compared to the lowest P4 dose. Treatment with ODB resulted in a delay in emergence of DF2 (4.2 (0.4) versus 2.0 (0.4) days (S.E.M.) to emergence for ODB versus no-ODB; P=0.01), a smaller maximum diameter of DF2 (15.2 (0.5) versus 17.9 (0.6)mm (S.E.M.) for ODB versus no-ODB; P <0.01), a shorter interval to maximum DF2 diameter (5.0 (0.3) versus 6.8 (0.3) days (S.E.M.) for ODB versus no-ODB; P=0.03), a shorter interval from DF2 emergence to ovulation (6.3 (0.4) versus 8.5 (0.4) days (S.E.M.) for ODB versus no-ODB; P=0.02) and a tendency for a lower average plasma P4 concentration post-ovulation (i.e. average of Days 15 and 22; 2.5 (0.4) versus 3.4 (0.4) ng/ml plasma P4 for ODB versus no-ODB, respectively; P=0.08). The DF present at device insertion, was still present at device removal in three (9%) cows of which two were treated with 1Q + no-ODB and one with 3Q + ODB. It is concluded that increasing P4 dose and ODB treatment are associated with a delay in subsequent follicle wave emergence and more rapid follicle growth. Oestradiol benzoate treatment also tends to reduce the plasma P4 concentration in the subsequent luteal phase in post-partum, anoestrous dairy cattle.

Production and Health of Pasture-Fed Dairy Cattle Following Oral Treatment with the Ionophore Lasalocid

The aim of the study was to evaluate the effect of feeding the ionophore lasalocid on the productivity and health of seasonally calving, pasture-fed dairy cows. Dairy cows (n = 1020) from 4 herds were enrolled in a split-herd, prospective intervention study. Cows were blocked by breed and age, ranked on previous production, and then assigned to 2 treatment groups. Treatment cows were each exposed to 300 to 350 mg of lasalocid/d commencing 3 wk before and ending 18 wk after the start of the seasonal calving period. Milk production was determined on 3 occasions for each cow at approximately monthly intervals (herd tests 1 to 3), body condition score was determined fortnightly, and all disease occurrences were recorded. Lasalocid treatment increased milk volume milk protein and milk fat production by approximately 2%, without altering milk composition. Fewer lasalocid-treated cows than control cows (7.3 vs. 11.6%, respectively) were diagnosed with clinical mastitis. Lasalocid treatment of pasture-fed dairy cows resulted in reduced mastitis incidence and increased milk production without changes in body condition or negative effects on metabolic processes as monitored by metabolite concentrations.

The use of hormonal treatments to improve the reproductive performance of lactating dairy cows in feedlot or pasture-based management systems

Hormonal interventions have been used to increase the probability of estrous detection and insemination, and to increase pregnancy rates of dairy cattle under a variety of management systems. The present review addresses the basic principles of hormonal intervention and presents typical examples that illustrate the methodology. The hormones used to control the estrous cycle mimic the reproductive hormones found within the normal cow. Most estrous synchronization systems employ a method for controlling follicular wave development, promoting ovulation in anestrous cows, regressing the corpus luteum in cyclic cows, and synchronizing estrus and (or) ovulation at the end of treatment. A wide range of reproductive systems are in place on dairy farms. In most herds, a non-intervention period is practiced where postpartum cows are observed estrus estrus. Cows not observed in estrus are then treated. A number of studies in pasture-based and confinement systems have demonstrated net benefits of whole-herd synchronization. Despite the advantages of whole-herd reproductive programs, their uptake has been inconsistent globally. The benefits of a timed artificial insemination (AI) system increase under conditions of poor estrous detection rate and poor conception rate. The unpopular nature of timed AI programs in pasture-fed cows relates to high rates of estrous detection and conception for pasture-based dairying. Regardless of production system, some cows must be re-inseminated because they are not pregnant after first insemination. The presence of "phantom cows" (non-pregnant cows that do not return to estrus) creates a serious reproductive challenge for both pasture-based and confinement-style operations. Early pregnancy diagnosis and second insemination timed AI may reduce the effects of phantom cows on dairy herds. Fundamental research into anestrous, the hormonal control of the estrous cycle, and early pregnancy detection should elucidate new methods that can be used to strengthen reproductive programs on dairy farms.

Duration of Infection and Strain Variation in Streptococcus uberis Isolated from Cows’ Milk

The duration of infection and pulsed-field gel electrophoresis (PFGE) types of bovine intramammary Streptococcus uberis isolates were examined. Milk samples were collected in duplicate from all 4 glands of 503 cows from 5 herds within 1 to 3 d of parturition and from 113 cows with clinical mastitis in the same herds throughout lactation. Glands from which S. uberis was isolated were resampled at 28-d intervals.The prevalence of S. uberis was 12% for cows around parturition, and the median duration of infection was 16 d. Cows >2 yr old had a longer duration of infection than 2 yr old cows, and duration varied among herds. A total of 173 different PFGE types were identified from a total of 234 S. uberis isolates. Each farm had a unique set of PFGE types. Only 3 PFGE types were common to each of 3 pairs of cows, and these occurred on the same farm. Where S. uberis was isolated on more than one occasion from a gland, only 55% of the PFGE types were the same across time. For cows with multiple glands infected, only one-half (9 of 18) had the same PFGE type in more than one gland. No predominant PFGE type was identified in any herd. It is concluded that there was wide heterogeneity of PFGE types, that the environment rather than other cows was the likely source of S. uberis infections, and that glands may be infected with multiple S. uberis PFGE types over a lactation.

Intramammary treatment of clinical mastitis of dairy cows with a combination of lincomycin and neomycin, or penicillin and dihydrostreptomycin

AIM

To compare clinical and bacteriological cure rates of clinical mastitis following treatment with intramammary preparations containing either lincomycin and neomycin or penicillin and dihydrostreptomycin.

METHODS

Cases of clinical mastitis were sourced from four seasonal-calving dairy herds in the central Waikato region of New Zealand during the first 120 days of lactation. Affected quarters were infused three times at 12 h intervals with either 333 mg lincomycin plus 100 mg neomycin (lin/neo; 197 glands),or 1,000 mg penicillin plus 500 mg dihydrostreptomycin (pen/DHS; 207 glands). Milk samples were collected for bacteriology from each quarter immediately before and approximately 21 days after initiation of treatment. Additionally, a composite milk sample from each cow was collected, on average, 54 days after enrolment for assessment of milk yield, composition and somatic cell count (SCC). The probability of bacterial cure was initially analysed using Chi-squared analysis, and factors that were associated (p<0.2) were offered to a reverse stepwise logistic regression model. Continuous variables (e.g. milk solids production and log10 SCC) were analysed using general linear models.

RESULTS

A total of 404 quarters diagnosed with clinical mastitis, from 282 cows in the first 120 days of lactation, were included. Streptococcus uberis, coagulase-negative staphylococci and Staphylococcus aureus were isolated from 56.5%, 18.8% and 10.0% of the bacteriologically positive quarters. There was no difference in the bacteriological cure rate (76.7% vs 76.7%, OR=0.94; p>0.8), the log10 SCC (2.1, SE 0.1, vs 2.0, SE 0.1; p>0.3) or milk production (1.2, SE 0.1, vs 1.2, SE 0.1, kg milksolids/cow/day; p>0.7) between lin/neo vs pen/DHS treatments, respectively. However, the proportion of cows re-treated following initial treatment was higher for the lin/neo compared to pen/DHS-treated group (16.3% vs 5.2%, OR=3.46; p<0.05).

CONCLUSIONS

No difference in bacteriological cure rate, milk production or SCC was evident between lin/neo and pen/DHS intramammary treatments for clinical mastitis in dairy cows during the first 120 days of lactation.

Resynchrony of previously anoestrous cows and treatment of cows not detected in oestrus that had a palpable corpus luteum with prostaglandin F2𝛂

AIMS

To determine if resynchrony, using a progesterone (P4) / oestradiol benzoate (ODB) regime, of previously treated, anovulatory anoestrous (AA) cows would increase the probability of oestrus, conception and pregnancy compared to no resynchrony. Additionally, the effect of prostaglandin F2alpha (PG) treatment of cows not detected in oestrus, but in which a corpus luteum (CL) was palpable transrectally (NDO/CL+), was compared with no treatment.

METHODS

Cows not detected in oestrus by 1 week before the start of the seasonal breeding programme were categorised as AA or NDO/CL+, based on absence or presence of a palpable CL, respectively. All AA cows were treated with an intravaginal device containing 1.36 g P4 (CIDR-B) for a period of 6 days, and with 1 mg ODB by intramuscular (I/M) injection 1 day after the device was removed (Day 0). Half the AA cows that were detected in oestrus between Days 0 and 3 were randomly assigned to be resynchronised by reinsertion of a clean used CIDR-B device on Day 15, for a period of 6 days, followed by an I/M injection of 0.5 mg ODB, 1 day after the device was removed (resynchrony, RS), while the other half were not resynchronised (no-RS). NDO/CL+ cows were alternately assigned to be either treated with 25 mg of the PG, dinoprost tromethamine, on Day 0 or left as untreated controls (Con).

RESULTS

Resynchrony increased the percentage of cows detected in oestrus between Days 14 and 28 (212/282 = 75.2% vs 155/285 = 54.4%, for RS vs no-RS, respectively; p<0.001), but had no effect on conception rate to a service within the first 3 days of the mating period (146/397 = 36.8% vs 148/399= 37.1%, for RS vs no-RS cows, respectively; p>0.9), or to a service between Days 14 and 28 (84/159 = 52.8% vs 114/217 = 52.5%, for RS vs no-RS cows, respectively; p>0.9). Resynchrony increased the Day 28 pregnancy rate (264/432 = 61.1% vs 237/435 = 54.5%, for RS vs no-RS cows, respectively; p=0.03), but had no effect on the Day 56 or final pregnancy rates (p>0.1).Prostaglandin treatment of NDO/CL+ cows did not affect the percentage of cows detected in oestrus by Day 7 (43/106 = 40.6% vs 51/101 = 50.5%, for Con vs PG, respectively; p=0.15), or Day 28 (92/106 = 86.8% vs 91/101 = 90.1%, for Con vs PG, respectively; p>0.4). Treatment did not affect the Day 28 pregnancy rate (55/103 = 53.4% vs 54/98 = 55.1%, for Con vs PG, respectively; p>0.9), the Day 56 pregnancy rate (81/103 = 78.6% vs 74/98 = 75.5%, for Con vs PG, respectively; p>0.6), or the final pregnancy rate (98/103 = 95.1% vs 89/97 = 91.8%, for Con vs PG, respectively; p>0.3).

CONCLUSIONS

Resynchrony of AA cows treated using the present protocol increased the proportion of non-pregnant cows detected in oestrus between Days 14 and 28 and increased the Day 28 pregnancy rate. This resynchrony protocol may be useful for increasing the proportion of the herd pregnant in the first month of the breeding programme, especially in herds that have a history of a low proportion of non-pregnant cows detected in oestrus between Days 14 and 28. There was no benefit in treating NDO/CL+ cows with PG compared to no treatment.

Invited review: Treatment of cows with an extended postpartum anestrous interval

Cows with an extended interval from calving to first ovulation (PPI) have increased intervals from calving to conception and are more likely to be culled compared with cows with a short PPI. In year-round calving dairy herds, between 11 and 38% of cows are reported as anestrus by 50 or 60 d after calving. In seasonally calving dairy herds, between 13 and 48% of cows are diagnosed as anovulatory anestrus at the start of the breeding period. Ovulation and estrus after calving are delayed when the positive feedback effects of estradiol on release of LH from the pituitary, and circulating concentrations of metabolic hormones such as insulin and insulin-like growth factor-I, are reduced by a variety of environmental factors. The main factors are limited energy intake, lower body reserves, increased partitioning of energy to milk production, suckling, and peripartum disease. Treatment options for cows with an extended PPI include hormonal and management strategies. Hormonal treatments that include a period of progesterone supplementation result in the majority of treated animals displaying estrus with a subsequent luteal phase of normal duration and improved pregnancy rates compared with untreated controls. Hormonal interventions also tend to have more predictable outcomes compared with management changes, such as manipulating body condition or dietary intakes after calving, and usually have some estrous synchronization effect, thus facilitating the use of artificial insemination. However, responses to any treatment are variable and are related to those factors that influence duration of the PPI, such as body condition and parity.

Management factors associated with the incidence of clinical mastitis over the non-lactation period and bulk tank somatic cell count during the subsequent lactation

AIM

To evaluate associations between management decisions related to the control of mastitis, including the infusion of antibiotics at the end of lactation (dry-cow therapy; DCT), on the incidence of clinical mastitis over the non-lactating period and the bulk tank somatic cell count (BTSCC) in the subsequent lactation.

METHODS

Dairy herd owners (n=158) provided information via a retrospective survey about (a) the proportion of their herds treated with DCT; (b) DCT management, including: number of occasions on which cows were dried off; manipulation of feed and water intake around drying off; infusion technique (partial vs full depth insertion of cannula); and hygiene before and after DCT infusion; (c) occurrence of mastitis and frequency of occurrence following drying off and in the subsequent lactation; (d) number of cows culled for mastitis-related conditions; (e) reasons for culling; (f) incidence of clinical mastitis; and (g) stock purchase policy with regard to mastitis. The BTSCC for each vat of milk supplied for the 1999/2000 and 2000/2001 seasons, and records of antibiotic purchases were collated for each herd. The probability that >2% of cows within a herd were diagnosed with clinical mastitis over the dry period was initially examined using univariate analysis (i.e. chi2 or logistic regression) and associated factors (p<0.2) were offered to a reverse stepwise logistic regression model. Factors hypothesised as being associated with the average lactation log10 BTSCC for the 2000/2001 season were initially examined using univariate analysis (i.e. ANOVA or linear regression analysis) and associated factors (p<0.2) were then tested using a forward manual model-building approach.

RESULTS

Increasing the percentage of the herd treated with DCT at the end of lactation was associated with reduced probability that >2% of a herd would be diagnosed with clinical mastitis over the non-lactating period and with a lower BTSCC in the subsequent lactation (p<0.01). A lower BTSCC was associated with small herds (<150 cows; p<0.05), not reducing feed intake around drying off (p<0.05), checking for clinical mastitis over the dry period in the milking parlour rather than at pasture (p<0.05), partial insertion of the DCT cannula (p<0.01), and use of 'change in udder shape' during lactation as a diagnostic criterion for mastitis (p<0.05). The incidence of clinical mastitis over the dry period was positively associated with reduced feeding around drying off (p=0.05) and the estimated volume of milk being produced at the time of drying off (p=0.014).

CONCLUSIONS

Use of dry cow therapy was associated with fewer cases of clinical mastitis over the non-lactating period and reduced BTSCC over the subsequent lactation. Reduced BTSCC was also associated with smaller herds, use of partial (compared with full depth) insertion of the DCT cannula, not reducing feed intake at the time of drying off, checking for clinical mastitis over the dry (non-lactation) period in the milking parlour, and use of udder shape for diagnosis during lactation. Control of clinical mastitis and BTSCC involves a range of management practices that need to be used in conjunction with DCT.

KEYWORDS

Dairy cows, mastitis, dry-cow therapy, somatic cell count, management practices.

Influence of estrus on somatic cell count in dairy goats

The effect of estrus on the somatic cell count (SCC) of goat's milk was examined by inducing estrus in 24 of 48 seasonally anestrus, lactating dairy goats. Goats were blocked by infection status and ranked on SCC from three preceding herd tests and randomly allocated (within block) to the following three treatment groups: a) "Short," in which an intravaginal progesterone-releasing device was inserted for 12 d plus equine chorionic gonadotropin and dinoprost tromethamine 2 d before device removal (n = 12), b) "Long," in which an intravaginal progesterone-releasing was inserted for 17 d plus equine chorionic gonadotropin on the day of device removal (n = 12), or c) "Control," in which the goats were left as untreated controls (n = 24). Bacteriological status of each gland of each goat was determined before and after synchronization (d -23 and +13) and SCC and milk volumes were determined on d -2, 0, 1, 2, 3, 4, 14, and 25, where d 0 was the day of intravaginal device removal. Goats in the Short group were in estrus before those of the Long group, who were, in turn, in estrus before the Control group. The log10 and log10 absolute SCC (SCC cells/ml x volume) were higher in the Short than in the Control group on d 1, 2, 3, and 4, whereas those of the Long group were higher than those of the Control group on d 2 and 4. These data indicate that estrus resulted in an increase in SCC, and that the increase in SCC was independent of the decline in milk volume at estrus.

Preferential recognition of a fragment species of osteoarthritic synovial fluid fibronectin by antibodies to the alternatively spliced EIIIA segment

OBJECTIVE

To characterize the species of synovial fluid (SF) fibronectin (FN) bearing the alternatively spliced EIIIA segment.

METHODS

SF from patients with osteoarthritis (OA) and rheumatoid arthritis (RA), as well as corresponding affinity isolation products, were subjected to 1-dimensional and 2-dimensional electrophoresis followed by Western blot analysis.

RESULTS

Regardless of the clinical type of arthritis, a polyclonal antibody that recognizes antigenic determinants throughout the FN molecule produced staining of predominantly approximately 200+ and approximately 170-kd species in reduced 1-dimensional electrophoresis. Despite the overall prevalence of the larger species, 4 monoclonal antibodies (mAb) reactive with sequences lying near the center of the EIIIA segment exhibited a relative failure to recognize the larger of these 2 species in OA, but not RA, SF. The absence of recognition of EIIIA sequences within the approximately 200+ kd forms of OA SF FN was unrelated to their derivation from dimers, since anti-EIIIA mAb recognized the smaller fragment species in preference to both monomeric and dimeric forms. The approximately 170-kd EIIIA+ fragments were observed to have minimal gelatin-binding capacity and appeared on 2-dimensional electrophoresis to extend from the N-terminus of FN through at least the center of the EIIIA segment. Similar results were obtained for samples obtained by needle aspiration or arthroscopic lavage, suggesting a widespread applicability of these findings.

CONCLUSION

The approximately 170-kd EIIIA+ species of FN could potentially constitute a soluble "vehicle" by which chondrocyte-regulating EIIIA sequences, liberated from inhibitory flanking C-terminal sequences, could reach cells in the arthritic joint. Additionally, "FN species-specific" recognition of this segment within OA SF could constitute a marker by which to gauge the activity of the OA disease process.

Treatment of anovulatory anoestrous postpartum dairy cows with a gonadotropin-releasing hormone (GnRH), prostaglandin F2𝛂, GnRH regimen or with progesterone and oestradiol benzoate

AIM

To compare 2 treatments for anovulatory anoestrus (AA) in postpartum dairy cows. The treatments were combinations of gonadotropin-releasing hormone (GnRH) and prostaglandin F2 (PG) or progesterone (P4) and oestradiol benzoate (ODB).

METHODS

Forty AA cows from each of 5 herds were blocked by age (2 or 2 years old) and randomly assigned to 1 of 2 treatments. The first group (GPG) were treated with 250 mug of a GnRH analogue, gonadorelin, followed 7 days later by 15 mg of the PG analogue, luprostiol. Two days later the cows were injected with 250 mug of gonadorelin. Cows were artificially inseminated 16-24 h after the second GnRH injection. The second group (P4+ODB) were treated with an intravaginal P4 releasing device for 6 days, followed 24 h after device removal by injection of 1 mg of ODB. Cows were pregnancy tested 35-40 days after the initial insemination and twice again at 6-8 week intervals thereafter.

RESULTS

There was no significant difference between P4+ODB and GPG groups in the percentage of cows submitted for insemination in the first 7 days (94.0% vs 100% for P4+ODB vs GPG, respectively; p>0.3), in conception rate to first insemination within the first 7 days (43.6% vs 35.0% for P4+ODB vs GPG, respectively; p>0.2), in the percentage of cows conceiving in the first 28 days of the breeding period (68.0% vs 58.3%, P4+ODB vs GPG, respectively; p>0.1), or in median interval from the end of treatment to conception (20 vs 21 days; p>0.1).

CONCLUSIONS

No differences in the reproductive performance of AA cows treated with either P4+ODB or GPG were detected. However, given the small number of animals enrolled, further data are required before the GPG protocol can be recommended for treatment of AA cows.

Reproductive performance of anovulatory anoestrous postpartum dairy cows following treatment with two progesterone and oestradiol benzoate-based protocols, with or without resynchrony

AIMS

(a) To compare the reproductive performance of anovulatory anoestrous (AA) postpartum dairy cows following treatment with 1 of 2 progesterone (P4) and oestradiol benzoate (ODB)-based treatment regimens; (b) To determine whether resynchronisation of cows initially treated for AA would improve reproductive performance and; (c) to determine whether cows not detected in oestrus but with a corpus luteum (CL) present (NDO/CL+), treated with P4 and ODB, would conceive earlier than untreated controls.

METHODS

Cows (n=1386) from 11 herds, that had not been detected in oestrus before the start of the seasonal mating period (PSM) and in which a CL was not detected were diagnosed AA, blocked by age (2 or >2 years old), then randomly assigned to be treated with an intravaginal P4-releasing device for either 6 (6-Day group) or 8 days (8-Day group). Cows in the 8-Day group were injected intramuscularly (IM) with 2 mg ODB at device insertion and all cows were injected with 1 mg ODB 24 h after device removal (Day 0). Cows detected in oestrus from Days 0-3 were subsequently assigned to be either resynchronised or left as untreated controls. Resynchronised cows had a used P4-releasing device reinserted on Day 14 for 8 days and were injected with 1 mg ODB at device reinsertion and again 24 h after device removal. NDO/CL+ cows were assigned to be either treated the same as the 8-Day group or left as untreated controls. All cows were inseminated on detection of oestrus and pregnancy tested approximately 10 weeks after the PSM and again 6-8 weeks after the end of the mating period.

RESULTS

For AA cows, the 14-day submission rate was similar between 6-Day and 8-Day groups (p0.1). However, the pregnancy rate by Day 14 was higher for the 8-Day than the 6Day group (43.0% vs 35.2%; p=0.006). Resynchrony treatment decreased the 14-day pregnancy rate compared with untreated controls (35.2% vs 42.5%; p=0.026). The resynchrony treatment increased the submission rate between Days 14-28 for non-pregnant cows compared with untreated controls (80.6% vs 57.4%; p=0.049). However, conception rate to resynchronised heats was lower than for cows that returned to oestrus naturally (56.6% vs 67.9%; p=0.025). Neither initial treatment type nor resynchrony treatment increased the 28-day pregnancy rate (p>0.1). There were no differences between treatment groups in the final non-pregnant rate (4.5% vs 4.6%; p>0.1). Treated NDO/CL+ cows had a higher 14-day submission rate (88.1% vs 49.4%; p>0.001), higher 14-day and 28-day pregnancy rates (42.9% vs 20.7%, p>0.001 and; 56.0% vs 42.5%, p=0.094, respectively) and conceived earlier (21 vs 36 days from PSM to median day of conception; p>0.05), than untreated NDO/CL+ cows.

CONCLUSIONS

The 8-Day, ODB-P4-ODB treatment regimen resulted in a higher pregnancy rate by 14 days but not 28 days than the 6-Day, P4-ODB treatment. The resynchrony treatment increased the proportion of non-pregnant cows inseminated on days 14-28, but did not increase the 28-day pregnancy rate or final pregnancy rate. Treatment of NDO/CL+ cows with the 8-Day, ODB-P4-ODB treatment improved reproductive performance compared with no treatment.

Effect of intrauterine antibiotic treatment on reproductive performance of dairy cows following periparturient disease

AIMS

To quantify the effect of treating lactating dairy cows that had histories of periparturient disorders or disease with a single intrauterine infusion of 0.5 g cephapirin, 3-6 weeks prior to the start of the seasonal breeding period.

METHODS

Cows (n=690) from spring-calving dairy herds (n=22) were enrolled in a prospective case-control study if they had a history of dystocia, a dead calf at calving or within 24 h of calving, retained foetal membranes (RFM), metabolic disease, twins or a vulval discharge 13 days postpartum. Cows were blocked by age, periparturient condition and calving date, and randomly assigned to be either treated with 0.5 g of cephapirin by intrauterine infusion, or left as untreated controls. Treatment occurred 24-42 days before the planned start of mating (PSM) within each herd. In addition, the reproductive tracts of 91 cows from 4 herds were examined using a vaginal speculum and rectal palpation and cervical-os discharge was scored on a scale from 0 (nil) to 3 (purulent).

RESULTS

Overall, more treated cows were retained in the trial herds until pregnancy testing than control cows (p0.05). Average 28-day submission rate was higher (93.1% vs 87.1%; p0.05) and PSM-to-first-service interval was shorter (9+/-1 vs 11+/-1 days; p0.05) in treated than control cows. The percentage of cows not pregnant at the end of the mating period was not affected by treatment overall. However, amongst cows diagnosed with RFM, a dead calf, or vulval discharge, pregnancy rates 28 and 56 days after PSM were higher for treated than control cows (p0.05). Cows with a purulent cervical-os discharge had lower 28-day submission rates (p0.01), lower 28-day pregnancy rates (p0.05) and higher non-pregnant rates at the end of mating than cows with nil or mucoid cervical-os discharges.

CONCLUSIONS

Intrauterine treatment with 0.5 g cephapirin improved reproductive performance of dairy cattle, especially those that had a history of RFM, a calf dead at calving or within 24 h of calving, or a vulval discharge.

Relationships among somatic cell count, California mastitis test, impedance and bacteriological status of milk in goats and sheep in early lactation

The objectives of this trial were to evaluate and compare the test characteristics of a number of indirect tests of bacteriological status of the milk from goats and sheep and to assess the affect of varying levels of prevalence of infection on the performance of those tests.The somatic cell count, California mastitis test (CMT) score, electrical impedance and the bacteriological status of 220 and 262 milk samples from the glands of lactating dairy goats and sheep, respectively, were determined. The sensitivity and specificity of indirect tests in predicting the bacteriological status were compared by analyzing the areas under the receiver operating characteristic curve and calculating the likelihood ratio at various cut-off values.Bacteria were isolated from 17.7 and 4.6% of glands from goats and sheep, respectively. Somatic cell count was a better predictor of bacteriological status than either the CMT score or impedance in both goats and sheep. However, knowledge of the CMT score in both sheep and goats and the impedance in goats increases the likelihood of predicting the presence of a bacterial pathogen compared to no testing at all (P<0.05). Knowledge of the age and days postpartum of the animals at the time of testing did not increase the probability that infection status could be predicted. Variation in cut-off levels to predict infection status reported in the literature may be due to variation in the prevalence of infection in the populations studied. Use of likelihood ratio allows comparison of tests over a range of prevalence's as likelihood ratios are independent of prevalence. The prevalence of infection within a herd should be considered when selecting a cut-off value for indirect testing for the presence of bacteria in milk of small ruminants.

Transcriptional regulation of alpha 2(I) collagen gene expression by fibroblast growth factor-2 in MC3T3-E1 osteoblast-like cells

Fibroblast growth factor-2 (FGF-2) stimulates proliferation and inhibits differentiated function of osteoblasts by suppressing synthesis of type I collagen and other proteins. However, little is known regarding the molecular mechanisms regulating the suppressive effects of FGF-2 on type I collagen synthesis in osteoblasts. The zinc finger transcription factor Egr-1 and the basic helix-loop-helix (bHLH) family of proteins have been implicated in the regulation of genes crucial to mesodermal cell growth and differentiation. The aim of this study was to determine whether Egr-1 and TWIST might be potential transcriptional regulators of the inhibitory effects of FGF-2 on alpha2(I) collagen expression in MC3T3-E1 osteoblasts which undergo a developmental sequence in vitro. Upon treatment of undifferentiated MC3T3-E1 cells with 1 nM FGF-2, Egr-1 mRNA increased with the effect maximal after 30-60 min. TWIST mRNA also increased with the effect maximal at 2 h. We analyzed the transcriptional control of alpha2(I) collagen gene expression by FGF-2 by transient transfection of an alpha2(I) collagen-luciferase construct (pH5) into undifferentiated MC3T3-E1 cells. The activity of the pH5 luciferase promoter decreased in a dose-dependent manner following treatment with.01 and 1 nM FGF-2. We identified putative Egr-1 and TWIST recognition sequences in the proximal region of the promoter for the murine alpha2(I) collagen gene and a putative Egr-1 site in the 5' region of the murine TWIST promoter. In gel mobility shift assays, potential Egr-1 response elements in the 5' region of the murine TWIST and alpha2(I) collagen genes demonstrated specific Egr-1 binding activity with bFGF-treated nuclear extracts obtained from MC3T3-E1 cells. These results indicate that Egr-1 and TWIST are expressed in undifferentiated MC3T3-E1 osteoblast-like cells following treatment with FGF-2 and they may be potential transcriptional regulators of FGF-2s negative effects on alpha2(I) collagen gene expression. J. Cell. Biochem. 80:550-559, 2001. Published 2001 Wiley-Liss, Inc.

Effects of periparturient diseases and conditions on the reproductive performance of New Zealand dairy cows

AIM

To determine the effect of retained foetal membranes (RFM), periparturient recumbency, calf mortality, dystocia, twin births and induction of parturition on submission and pregnancy rates of pasture-fed, seasonally-calving dairy cows in New Zealand.

METHODS

Data were retrospectively collected for 2652 cows from 11 herds on the occurrence of periparturient diseases and condition, calving date, age and treatment for anoestrus prior to the planned start of mating (PSM). The effects of each disease or condition on submission and pregnancy rate by 28 days after PSM, final pregnancy rate, and the proportion of cows that conceived more than 50 days after PSM were examined using separate logistic regression models. Results are expressed as odds ratios (OR). Additionally, the effect of each disease or condition on the interval from PSM to conception was examined using survival analysis. Age, herd and late calving (i.e. cows calved < or =40 days before PSM) were included as factors in the models examined.

RESULTS

Induction of parturition increased the risk of RFM (OR=3.3, p<0.01). The 28-day submission rate was affected by age and herd but not by any of the periparturient conditions examined. The 28-day pregnancy rate was reduced by RFM (OR=0.04, p<0.05), induction of parturition (OR=0.67, p<0.01), assisted calving (OR=0.61, p<0.01), late calving (OR=0.55, p<0.05) and anoestrus (OR=0.27, p<0.05). The final pregnancy rate was reduced by RFM (OR=0.013, p<0.01), induction (OR=0.25, p<0.05), assisted calving (OR=0.30, p<0.005) and anoestrus (OR=0.32, p<0.05), and was increased if the cow was submitted for mating within 28 days after PSM (OR=2.72, p<0.05). Effects of recumbency and twinning were not significant in any of the models.

CONCLUSIONS

Cows that had had RFM or were assisted, induced or late to calve, had significantly lower pregnancy rates or took longer to conceive than unaffected herd-mates.

CLINICAL RELEVANCE

Intervention programs aimed at the examination and treatment of cows with periparturient conditions may improve the reproductive performance of New Zealand dairy herds. Investigations of poor reproductive performance of a herd should include analysis of the prevalence and effects of periparturient diseases and conditions.

The leisure satisfaction of people with psychiatric disabilities

Leisure is considered to be an important part of life for every individual. This is even more so for people who have limited employment prospects and life options. The primary handicaps associated with mental illness create problems with social relationships and can hinder individuals from participating in or enjoying leisure pursuits. The aim of this exploratory study was to examine leisure satisfaction in a sample of one hundred adults with a mental illness who were clients of an Australian community mental health rehabilitation service. The Leisure Satisfaction Survey and the Life Skills Profile were administered to these clients to determine their leisure satisfaction and general functioning. Contrary to expectations, results indicated that the clients of mental health rehabilitation services believe that their leisure pursuits provide them with intellectual stimulation, enjoyable relationships with others and relaxation, suggesting that they are very satisfied with the activities they engage in during their leisure time. In general, these clients were more satisfied with their leisure than the normative population. Consistent with expectations, clients with lower disability and in particular with high capacity for social contact were most satisfied with their leisure pursuits. The significance of these results and the utility of the Leisure Satisfaction Survey with this population are discussed.

Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin

ELOXATIN (Oxaliplatin) is a novel platinum containing anti-cancer agent with a diaminocyclohexane carrier ligand which has been approved in several major European countries. Clinical studies have demonstrated that the compound exhibits marked activity against colorectal cancers in combination with 5-fluorouracil (5-FU). The aim of this work was to develop and validate a highly sensitive inductively coupled plasma mass spectrometry assay for the determination of oxaliplatin-derived platinum in plasma ultrafiltrate, plasma and whole blood and to apply this technique to clinical pharmacokinetic studies with oxaliplatin. Ultratrace detection of platinum in plasma ultrafiltrate was achieved using ultrasonic nebulisation combined with ICP-MS. This technique allows detection of platinum at the 0.001 microg Pt/ml level in only 100 microl of matrix. Assays in blood and plasma utilised a standard Meinhardt nebuliser and spray chamber, achieving detection limits of 0.1 microg Pt/ml in 100 and 200 microl of matrix, respectively. The assays were validated (accuracy and precision within +/- 15%) over the concentration ranges: 0.001-0.250 microg Pt/ml in plasma ultrafiltrate and 0.1-10 microg Pt/ml for plasma and whole blood. The effect of sample digestion. dilution, long term frozen storage and quantitation in the presence of 5-FU were also investigated and validated. The method was used to monitor platinum exposure following oxaliplatin administration (130 mg/m2) to cancer patients. Following a 2 h i.v. infusion, peak platinum levels declined in a triphasic manner in all blood compartments. Free platinum was detected in plasma ultrafiltrate at low levels (0.001 0.010 microg Pt/ml) for up to 3 weeks. In conclusion, a highly sensitive and specific assay has been developed for the determination of platinum in biofluids. This method enabled characterisation of the long term exposure to platinum in patients following oxaliplatin treatment.

Treatment of noncyclic lactating dairy cows with progesterone and estradiol or with progesterone, GnRH, prostaglandin F2 alpha, and estradiol

The efficacy of two programs for treating noncyclic cows was compared. In trial 1, 478 cows in five herds were randomly divided into two groups. Cows in one group (C group) were treated with an intravaginal progesterone device for 8 d followed in 48 h by 1 mg of estradiol benzoate to cows that had not been detected in estrus since device removal. Those in the other group (CGP group) were treated with progesterone and estradiol as for the C group plus 10 micrograms of a GnRH agonist (buserelin) at device insertion and 25 mg of PGF2 alpha 7 d after device insertion. In trial 2 with 729 cows in nine herds, the treatments were similar to those in trial 1 except that the duration of progesterone treatment was 7 d. No significant difference was found between trials and results from both trials were combined. Compared with C group cows, CGP group cows had a greater estrous response rate (93.2 vs. 89.1%), a greater conception rate to first artificial insemination (AI, 47.1 vs. 29.4%), marginally lower conception rate to second AI (52.9 vs. 59.7%), lower nonpregnancy rate (8.3 vs. 11.1%), and shorter intervals from the start of breeding to conception by AI (9.8 vs. 15.3 d) or by AI or natural mating (21.6 vs. 26.3 d). The treatment protocol used for the CGP group achieved better reproductive performance than that used for the C group.